We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App





Sentinel Diagnostics Develops Ready-To-Use Real-Time PCR Mix for Detection of Novel Coronavirus

By LabMedica International staff writers
Posted on 18 Mar 2020
Print article
Image: STAT-NAT® COVID-19 Assay (Photo courtesy of Sentinel Diagnostics)
Image: STAT-NAT® COVID-19 Assay (Photo courtesy of Sentinel Diagnostics)
Sentinel Diagnostics (Milan, Italy) has announced that it has developed a ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease (COVID-19). Sentinel has developed two kits in collaboration with the most important hospital lab for the detection and treatment of coronavirus in Italy.

Sentinel is focused on the development and production of in vitro diagnostics (IVD) for the most advanced clinical chemistry, immunochemistry and molecular diagnostics platforms. Besides its wide product portfolio in clinical chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the last 12 years, the company has grown in the molecular diagnostics sector and has developed the proprietary technology STAT-NAT®, able to stabilize the activity of PCR mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.

Sentinel’s STAT-NAT® COVID-19 assay is a freeze-dried ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease in human respiratory tract specimens in about 90 minutes. The company has developed two versions of this kit, which follow two international protocols for the highest sensitivity and specificity. STAT-NAT® COVID-19 HK kit is based on the Hong Kong protocol, while STAT-NAT® COVID-19 B assay follows the Berlin protocol. Both these kits are validated on the most common PCR instruments and have been tested on human respiratory tract specimens found positive.

“The R&D NAT team has developed and tested the COVID-19 assay by working side by side with one of the reference hospital labs for the detection and treatment of coronavirus in Italy” said Maurizio Gramegna, Chief Technology Officer at Sentinel Diagnostics. “Both STAT-NAT® COVID-19 HK and B are compliant with the international protocols and are able to detect the relevant genetic variants of Coronavirus COVID-19. We are always in touch with KOLs, in order to keep the assays up to date and even update them in case of any virus mutation.”

Related Links:
Sentinel Diagnostics

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.